/
HOWL
$0.31-$0.02 (-4.64%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$15.7M
49M shares
52-week range
$0.27 – $2.38
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-17.13
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $16.4M | $19.9M | $1.9M | $0 |
| Cost of revenue | $463.0K | $777.0K | $0 | $2.5M | $1.8M | $1.8M | $1.6M |
| Gross profit | −$463.0K | −$777.0K | $0 | $13.9M | $18.2M | $71.0K | −$1.6M |
| Gross margin | — | — | — | 84.7% | 91.2% | 3.8% | — |
| R&D | $6.3M | $16.6M | $35.3M | $53.8M | $41.8M | $56.4M | $44.8M |
| Operating income | −$9.9M | −$22.4M | −$50.1M | −$56.1M | −$40.5M | −$73.6M | −$60.7M |
| EBITDA | −$9.4M | −$14.3M | −$49.8M | −$51.3M | −$32.5M | −$64.0M | −$53.9M |
| Net income | −$11.0M | −$14.9M | −$50.0M | −$53.8M | −$37.4M | −$70.5M | −$60.8M |
| Net margin | — | — | — | -328.1% | -187.4% | -3740.8% | — |
| EPS (diluted) | -0.38 | -0.98 | -10.94 | -1.86 | -1.05 | -1.63 | -1.33 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.89 | $-1.05–$-0.73 | 2 |
| 2027 | $3M | $-1.59 | $-1.59–$-1.59 | 1 |
| 2028 | $50000 | $-1.47 | $-1.47–$-1.47 | 1 |
| 2029 | $18M | $-0.98 | $-0.98–$-0.98 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.02
Price
$0.31
Implied upside
+232%
Peer comparison
Werewolf Therapeutics, Inc. Common Stock
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
www.werewolftx.com- Employees
- 14
- IPO / List date
- Apr 30, 2021
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds HOWL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 516,218 | $429.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HOWL yet.
